



## Total Voting Rights

June 28, 2024

RNS Number : 2377U  
Renalytix PLC  
28 June 2024

### Renalytix plc ("Renalytix" or the "Company")

#### Total Voting Rights

**LONDON and NEW YORK, 28 June 2024** - [Renalytix plc](https://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX) announces that at today's date, the Company's total issued share capital is 154,368,191 Ordinary Shares of £0.0025 each in the capital of the Company ("Ordinary Shares"). Each Ordinary Share carries the right to one vote at a general meeting of the Company. The Company does not hold any Ordinary Shares in treasury.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

***For further information, please contact:***

**Renalytix plc**

James McCullough, CEO

[www.renalytix.com](https://www.renalytix.com)

**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore / Nick Harland / Samira  
Essebiyea

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**

Gary Clarence / Shalin Bhamra

**Tel: 020 7597 4000**

**Walbrook PR Limited**

Paul McManus / Alice Woodings

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07407 804 654

**CapComm Partners**

Peter DeNardo

**Tel: 415-389-6400** or [investors@renalytix.com](mailto:investors@renalytix.com)

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled *in-vitro* diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRQKOBABKDOAB